非肿瘤性疾病患者的血清CA 15.3水平及肿瘤活性阈值的确定。1219例患者的结果。 - Suppr | 超能文献

Serum CA 15.3 levels in patients with non-tumoral diseases, and establishment of a threshold for tumoral activity. Results in 1219 patients.

作者信息

Ruibal A, Genollá J, Rosell M, Gris J M, Colomer R

出版信息

Int J Biol Markers. 1986 Sep-Dec;1(3):159-60. doi: 10.1177/172460088600100308.

DOI:10.1177/172460088600100308

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Serum CA 15.3 levels in patients with non-tumoral diseases, and establishment of a threshold for tumoral activity. Results in 1219 patients.非肿瘤性疾病患者的血清CA 15.3水平及肿瘤活性阈值的确定。1219例患者的结果。

Int J Biol Markers. 1986 Sep-Dec;1(3):159-60. doi: 10.1177/172460088600100308.

2

CA 15.3 as a tumour marker in breast cancer.CA 15.3作为乳腺癌的肿瘤标志物。

Int J Biol Markers. 1987 Sep-Dec;2(3):135-42. doi: 10.1177/172460088700200301.

3

[Clinical evaluation of a cancer antigen, CA 15-3, associated with breast cancer. (I) Modification of its method and reference values].

Rinsho Byori. 1986 Jan;34(1):53-8.

4

[Serum CA 15.3 in women with non-tumor breast pathologies. Initial results].

Med Clin (Barc). 1986 Sep 27;87(9):393-4.

5

Serum BCM levels in patients with non-tumoral pathologies: a value of 25 U/ml can be used as threshold for tumoral activity.

Int J Biol Markers. 1990 Jan-Mar;5(1):50-1. doi: 10.1177/172460089000500112.

6

Clinical evaluation of a new tumour marker TAG 12 in breast cancer.一种新型肿瘤标志物TAG 12在乳腺癌中的临床评估

Anticancer Res. 1991 Mar-Apr;11(2):805-8.

7

CA-125 monitoring during chemotherapy for ovarian cancer.

Int J Biol Markers. 1986 Sep-Dec;1(3):121-8. doi: 10.1177/172460088600100302.

8

Clinical significance of CA125 and its assessment with an enzyme immunoassay.

Asia Oceania J Obstet Gynaecol. 1987 Sep;13(3):325-33. doi: 10.1111/j.1447-0756.1987.tb00273.x.

9

Serum MCA, CA 125 and CA 19.9 determination in primary breast cancer.

Biochem Soc Trans. 1996 May;24(2):302S. doi: 10.1042/bst024302s.

10

Localisation of Ca and HMFG2 antigens in breast tissue by immunoperoxidase, immunofluorescence, and immunoelectron microscopy.通过免疫过氧化物酶、免疫荧光和免疫电子显微镜对乳腺组织中的钙和HMFG2抗原进行定位。

J Clin Pathol. 1985 May;38(5):512-20. doi: 10.1136/jcp.38.5.512.

引用本文的文献

1

Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.2-[18F]氟-2-脱氧-D-葡萄糖正电子发射断层扫描/计算机断层扫描在乳腺癌治疗后监测中的作用

PLoS One. 2014 Dec 17;9(12):e115127. doi: 10.1371/journal.pone.0115127. eCollection 2014.

2

CA15.3 serum concentrations in older women with infiltrating ductal carcinomas of the breast.老年女性浸润性乳腺导管癌患者的CA15.3血清浓度

Int J Mol Sci. 2014 Oct 31;15(11):19870-6. doi: 10.3390/ijms151119870.

3

Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.血清CA15-3联合癌胚抗原（CEA）和组织多肽抗原（TPA）检测在乳腺癌患者术后随访中的应用评估

Br J Cancer. 1991 Jul;64(1):154-8. doi: 10.1038/bjc.1991.260.